Cohort profile: The Janus serum bank cohort in Norway

International Journal of Epidemiology

Volumn 46, Issue 2, 2017, Pages 403-404G

  Langseth, Hilde ^a   Gislefoss, Randi E ^a   Martinsen, Jan I ^a   Dillner, Joakim ^b,c   Ursin, Giske ^a,d,e  

^a CANCER REGISTRY OF NORWAY   (Norway)

^b KAROLINSKA INSTITUTE   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d UNIVERSITY OF OSLO   (Norway)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

BIOMARKER; CANCER; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; DATABASE; DETECTION METHOD; HEALTH SURVEY; PUBLIC HEALTH; SERUM; TUMOR;

BIOBANK; BLOOD DONOR; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; HEALTH SURVEY; HUMAN; MASS SCREENING; PRIORITY JOURNAL; PROGNOSIS; QUESTIONNAIRE; RED CROSS; REVIEW; ADULT; AGE DISTRIBUTION; AGED; BLOOD; BLOOD BANK; CRYOPRESERVATION; FEMALE; MALE; MIDDLE AGED; NEOPLASM; NORWAY; PROSPECTIVE STUDY; REGISTER; SEX RATIO; SPECIMEN HANDLING; VERY ELDERLY;

NORWAY;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BLOOD BANKS; CRYOPRESERVATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NORWAY; PROSPECTIVE STUDIES; REGISTRIES; SEX DISTRIBUTION; SPECIMEN HANDLING;

EID: 85054030357     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyw027     Document Type: Review

References (33)

1. Torgersen O. [The Janus project]. Tidsskr Nor Laegeforen 1975;95:1611–13.
2. Leren P, Askevold EM, Foss OP. et al. The Oslo study. Cardiovascular disease in middle-aged and young Oslo men. Acta Med Scand Suppl 1975;588:1–38.
3. Bjartveit K, Foss OP, Gjervig T. The cardiovascular disease study in Norwegian counties. Results from first screening. Acta Med Scand Suppl 1983;675:1–184.
4. Bjartveit K, Foss OP, Gjervig T, Lund-Larsen PG. The cardiovascular disease study in Norwegian counties. Background and organization. Acta Med Scand Suppl 1979;634:1–70.
5. Aires N, Selmer R, Thelle D. The validity of self-reported leisure time physical activity, and its relationship to serum cholesterol, blood pressure and body mass index. A population based study of 332,182 men and women aged 40-42 years. Eur J Epidemiol 2003;18:479–85.
6. Larsen IK, Småstuen M, Johannesen TB. et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer 2009;45(7):1218–31.
7. Langseth H, Luostarinen T, Bray F, Dillner J. Ensuring quality in studies linking cancer registries and biobanks. Acta Oncol 2010;49:368–77.
8. Gislefoss RE, Grimsrud TK, Morkrid L. Long-term stability of serum components in the Janus Serum Bank. Scand J Clin Lab Invest 2008:68:402–09.
9. Gislefoss RE, Grimsrud TK, Morkrid L. Stability of selected serum proteins after long-term storage in the Janus Serum Bank. Clin Chem Lab Med 2009;47:596–603.
10. Hustad S, Eussen S, Midttun O. et al. Kinetic modeling of storage effects on biomarkers related to B vitamin status and one-carbon metabolism. Clin Chem 2012;58:402–10.
11. Hannisdal R, Gislefoss RE, Grimsrud TK. et al. Analytical recovery of folate and its degradation products in human serum stored at -25 degrees C for up to 29 years. J Nutr 2010;140:522–26.
12. Gislefoss RE, Grimsrud TK, Morkrid L. Stability of selected serum hormones and lipids after long-term storage in the Janus Serum Bank. Clin Biochem 2015;48:364–69.
13. Rounge TB, Lauritzen M, Langseth H. et al. microRNA Biomarker Discovery and High-Throughput DNA Sequencing Are Possible Using Long-term Archived Serum Samples. Cancer Epidemiol Biomarkers Prev 2015;24:1381–87.
14. Dillner J, Lehtinen M, Bjorge T. et al. Prospective seroepide-miologic study of human papillomavirus infection as a risk factor for invasive cervical cancer. J Natl Cancer Inst 1997;89:1293–99.
15. Mork J, Lie AK, Glattre E. et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 2001;344:1125–31.
16. Bjorge T, Hakulinen T, Engeland A. et al. A prospective, seroepi-demiological study of the role of human papillomavirus in esophageal cancer in Norway. Cancer Res 1997;57:3989–92.
17. Bjorge T, Engeland A, Luostarinen T. et al. Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study. Br J Cancer 2002;87:61–64.
18. Andersson K, Luostarinen T, Strand AS. et al. Prospective study of genital human papillomaviruses and nonmelanoma skin cancer. Int J Cancer 2013;133:1840–45.
19. de Vogel S, Meyer K, Fredriksen A. et al. Serum folate and vitamin B12 concentrations in relation to prostate cancer risk – a Norwegian population-based nested case-control study of 3000 cases and 3000 controls within the JANUS cohort. Int J Epidemiol 2013;42:201–10.
20. Schwartzbaum J, Ding B, Johannesen TB. et al. Association between prediagnostic IgE levels and risk of glioma. J Natl Cancer Inst 2012;104:1251–59.
21. Engel LS, Laden F, Andersen A. et al. Polychlorinated biphenyl levels in peripheral blood and non-Hodgkin’s lymphoma: a report from three cohorts. Cancer Res 2007;67:5545–52.
22. Koutros S, Langseth H, Grimsrud TK. et al. Prediagnostic Serum Organochlorine Concentrations and Metastatic Prostate Cancer: A Nested Case-Control Study in the Norwegian Janus Serum Bank Cohort. Environ Health Perspect 2015. doi:10.1289/ ehp.1408245.
23. Purdue MP, Engel LS, Langseth H. et al. Prediagnostic serum concentrations of organochlorine compounds and risk of testicular germ cell tumors. Environ Health Perspect 2009;117:1514–19.
24. Ward EM, Schulte P, Grajewski B. et al. Serum organochlorine levels and breast cancer: a nested case-control study of Norwegian women. Cancer Epidemiol Biomarkers Prev 2000;9:1357–67.
25. Paus E, Theodorsen L, Engeland A. Prostate-specific antigen in serum from blood donors with subsequent prostate cancer diagnosis. Eur J Cancer1993;29A:1221–22.
26. Zurawski VR Jr, Orjaseter H, Andersen A, Jellum E. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int J Cancer 1988;42:677–80.
27. Keller A, Leidinger P, Gislefoss R. et al. Stable serum miRNA profiles as potential tool for non-invasive lung cancer diagnosis. RNA Biol 2011;8:506–16.
28. Tretli S, Hernes E, Berg JP, Hestvik UE, Robsahm TE. Association between serum 25(OH)D and death from prostate cancer. Br J Cancer 2009;100:450–54.
29. Tretli S, Schwartz GG, Torjesen PA, Robsahm TE. Serum levels of 25-hydroxyvitamin D and survival in Norwegian patients with cancer of breast, colon, lung, and lymphoma: a population-based study. Cancer Causes Control 2012;23:363–70.
30. Ekstrom PO, Bjorge T, Dorum A. et al. Determination of hereditary mutations in the BRCA1 gene using archived serum samples and capillary electrophoresis. Anal Chem 2004;76:4406–09.
31. Ulvik A, Vollset SE, Hansen S. et al. Colorectal cancer and the methylenetetrahydrofolate reductase 677C -> T and methionine synthase 2756A -> G polymorphisms: a study of 2,168 case-control pairs from the JANUS cohort. Cancer Epidemiol Biomarkers Prev 2004;13:2175–80.
32. Bjorge T, Lie AK, Hovig E. et al. BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study. Br J Cancer 2004;91:1829–34.
33. Wibom C, Spath F, Dahlin AM. et al. Investigation of established genetic risk variants for glioma in prediagnostic samples from a population-based nested case-control study. Cancer Epidemiol Biomarkers Prev 2015;24:810–16.